A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Tag: Xarelto

  • Apixaban (Eliquis) News – Plus Update On The Big Four New Oral Anticoagulants

    There is a lot of appropriate interest and excitement today about one of the four new oral anticoagulants in development – Apixaban (Eliquis). Data from the large ARISTOTLE trial were published today in the NEJM, showing that in patients with atrial fibrillation Apixaban was more effective in preventing stroke and systemic thromboembolism, caused less major bleeding, and resulted…

  • Eliquis (Apixaban) News – Plus Update On The Big Four New Oral Anticoagulants

    There is a lot of appropriate interest and excitement today about one of the four new blood thinners in development – Apixaban (Eliquis). Data from the large atrial fibrillation trial called ARISTOTLE were published today and show that the drug is more effective and safer than warfarin in patients with atrial fibrillation [ref 1].  This…

  • Prescription assistance: when you can’t afford a medication

    Beth Waldron, Program Director of the Clot Connect project, writes…. Approximately 1 in 5 people don’t take a medication a doctor has prescribed because they can’t afford to pay for it [ref 1].  While the cost of some outpatient “blood thinning” therapies (anticoagulants) can be substantial, failure to take a blood thinning medication as prescribed…

  • Prescription Assistance: When Patients Can’t Afford a Medication

    Beth Waldron, Program Director of the Clot Connect project, writes…. While the cost of some outpatient anticoagulation therapies can be substantial, failure to take an anticoagulant medication as prescribed can have serious, even deadly, consequences.   Links to resources which may help patients when they are prescribed an anticoagulant that they cannot afford is available in this article.…

  • Xarelto (Rivaroxaban) – FDA Approved

    Today the FDA approved the oral anticoagulant Xarelto (rivaroxaban) for DVT prevention in patients undergoing knee or hip replacement surgery.  This is good news

  • Xarelto (Rivaroxaban) – FDA Approved

    On July 1st, the FDA approved the oral blood thinner Xarelto (rivaroxaban) for the prevention of deep vein thrombosis (DVT) in patients undergoing  knee or hip replacement surgery.

  • Xarelto® – Good News

    Summary Good news. A major study published in December 2010 in the  New England Journal of Medicine (NEJM) shows that the new oral “blood thinner” Xarelto® (=Rivaroxaban) is (a) as safe and effective as warfarin in patients with acute DVT, and (b) is quite effective in preventing recurrent venous thromboembolism if taken longer-term, with an…

  • Xarelto® – Good News

    Summary Good news. A major study published in December 2010 in the prestigious New England Journal of Medicine (NEJM) shows that the new oral “blood thinner” Xarelto® (=Rivaroxaban) is (a) as safe and effective as warfarin in patients with acute deep vein thrombosis (DVT), and (b) is quite effective in preventing recurrent blood clots (DVT…